… study was a significant predictive factor for erlotinib therapy. … of gefitinib and erlotinib could
be performed in our study. Thus, … of sensitivity to erlotinib therapy after gefitinib failure. Further …

… were enrolled in this study, and 12 patients were treated (five men and … treated with afatinib
20 mg/day, three patients were treated with afatinib 40 mg/day and six patients were treated …

… Thus, in the present study, we investigated the plasma and … -TKI treatment (250 mg daily
gefitinib or 150 mg daily erlotinib) … 15 patients received gefitinib and erlotinib treatment; therefore…

… as first-line therapy for advanced NSCLC, gefitinib was associated with a … gefitinib. We do
not believe that there is a need to a head-to-head clinical trial between gefinitib and erlotinib; …

… therapy with gefitinib 250 mg daily after thorough discussion … to gefitinib treatment can
be safely switched to erlotinib. In … CR by the first patient on erlotinib suggests that anti-tumor …

… -line therapy is still a controversial issue. The aim of this study was to compare the effectiveness
of gefitinib, erlotinib, and … NSCLC including 147 patients treated with EGFR TKIs. Time to …

… No relevant systematic reviews that answered our research questions were identified. …
The os with gefitinib therapy trended longer in the mutation-positive subgroup (hr: 0.78; 95% ci: …

… treated with erlotinib after progression of disease to gefitinib. … suggested that erlotinib could
be more efficacious than gefitinib, … out a study to evaluate the activity of erlotinib in advanced …

… , but patients with exon 20 point mutations from another phase I study (NCT02113813)
without available standard-of-care therapies could continue ASP8273 under revised consent …

… study, the primary objective was to determine the pooled overall treatment effect on OS of
firstline therapy with gefitinib … this meta-analysis of gefitinib and erlotinib as most of the included …